Status:
COMPLETED
Effect of Dosing Time and Meal on IN-105 (Insulin Tregopil) PK and PD
Lead Sponsor:
Biocon Limited
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
A study to evaluate the PK and PD of oral IN-105 (Insulin Tregopil) w.r.t. time of dosing prior to meal, duration between meals and type of meal .
Detailed Description
A Phase 1, Randomized, Placebo Controlled, Crossover Trial in Type 2 Diabetes Patients to evaluate the effect of pre-meal dosing time, inter-meal interval and meal composition on the PK and PD of IN-1...
Eligibility Criteria
Inclusion
- Patient should have an established diagnosis of T2DM per ADA 2013 criteria for at least 1 year prior to screening and are on metformin treatment for at least a month before screening.
- Body mass index (BMI) of 18.5 to 40.00 kg/m2, both inclusive
- Glycosylated hemoglobin (HbA1c) ≤ 9.5%.
- Hemoglobin ≥9.0 g/dL.
- No clinically significant abnormality in the ECG at screening.
- Fasting plasma glucose levels less than 140 mg/dL at screening.
- The patient should be ready to give a written and signed informed consent before starting any protocol-specific procedures.
Exclusion
- History of hypersensitivity to insulins or insulin analogues.
- Evidence of the following (either due to improper diabetes control or due to secondary complications following diabetes).
- History of ≥2 episodes of severe hypoglycemia within 6 months before screening or history of hypoglycemia unawareness as judged by the investigator.
- History of ≥1 episodes of hyperglycemic hyperosmolar state or emergency room visits for uncontrolled diabetes leading to hospitalization in the 6 months prior to screening.
- History of limb amputation as a complication of diabetes during his/her lifetime or any vascular procedure during the 1 year prior to screening.
- History of diabetic foot or diabetic ulcers in the past 1 year prior to screening.
- History of severe form of neuropathy or cardiac autonomic neuropathy (determined when obtaining patient history).
- Presence of any of the following:
- Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HBsAg) or hepatitis C infection at screening.
- Any clinically significant abnormality in the safety laboratory tests conducted at screening.
- Impaired hepatic function at screening \[alanine transaminase (ALT) or aspartate aminotransferase (AST) value \>2 times the upper limit of the reference range and/or serum bilirubin 1.5 times the upper limit of the reference range\] which investigator considers clinically significant.
- Evidence of clinically significant chronic renal disease (e.g. nephrotic syndrome, diabetic nephropathy) as assessed by the investigator at screening
- History or use of the following:
- Patients on OADs other than metformin for previous three months prior to screening.
- Patients who have received ≥14 consecutive days of oral, intravenous, or inhaled glucocorticoid therapy within the past 1 year or have received steroids by any route within 4 weeks immediately preceding screening visit (intra-nasal, intra ocular, and topical steroid use is allowed).
- Receipt of another investigational drug in the 4 weeks prior to screening, or within 5 half-lives of the another investigational drug at screening visit (whichever is longer), or scheduled for another investigational drug during the current study period.
Key Trial Info
Start Date :
March 27 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT03392961
Start Date
March 27 2014
End Date
July 1 2014
Last Update
January 23 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.